Insulin resistance and blood pressure

Current Hypertension Reports

Volumn 10, Issue 4, 2008, Pages 319-325

  Addison, Sonya ^b   Stas, Sameer ^b   Hayden, Melvin R ^b   Sowers, James R ^a  

^a University of Missouri   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; NIFEDIPINE; RENIN INHIBITOR; ROSIGLITAZONE; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; CARDIOVASCULAR AGENT; MINERALOCORTICOID RECEPTOR; RENIN;

ADJUVANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EXERCISE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; DRUG ANTAGONISM; LIFESTYLE; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFE STYLE; OBESITY; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 52449104443     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0059-1     Document Type: Review

References (43)

1. Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
3. Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
4. Schutta MH: Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007, 2:124-130.
5. Garcia-Puig J, Ruilope LM, Luque M, et al.: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318-326.
6. Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602.
7. Nistala, R, Stump CS: Skeletal muscle insulin resistance is fundamental to the cardiometabotic syndrome. J Cardiometab Syndr 2006, 1:47-52.
8. El-Atat F, Ashish A, Mcfarlane S, Sowers J: Obesity and hypertension. Endrinol Metab Clin N Am 2003, 32:823-854.
9. Takata Y, Osawa H, Krata M, et al.: Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51:534-539.
10. Diamant M, Tushuizen M: The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD? Curr Diab Rep 2006, 6:279-286.
11. Clasen R, Schupp M, Foryst-Ludwig A, et al.: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
12. Sowers JR: The role of c-reactive protein in the metabolic syndrome and diabetes mellitus. Endocrinologist 2007, 17:163-168.
13. Cooper SA, Whaley-Connell A, Habibi J, et al.: Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2209-H2223.
14. Stas S, Whaley-Connell A, Sowers JR: Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008, 10:94-96.
15. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
16. Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855-861.
17. Brouwer BG, Visseren FLJ, van der Graff Y: The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. Am Heart J 2007, 154:1146-1152.
18. Lakka TA, Lakka HM, Rankinen T, et al.: Effect of exercise training on plasma levels of c-reactive protein in healthy adults: the heritage family study. Eur Heart J 2005, 26:2018-2025.
19. McKeown N, Meigs JB, Liu S, et al.: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27:538-546.
20. Lutsey PL, Steffen LM, Stevens J.: Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC). Circulation 2008, 117:754-761.
21. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:1-7.
22. Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065-1070.
23. Shargorodsky M, Boaz M, Davidovitz I, et al.: Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. J Cardiometab Syndr 2007, 2:16-23.
24. Stas S, Appesh L, Sowers JR: Metabolic safety of antihypertensive drugs: myth vs. reality. Curr Hypertens Rep 2006, 8:403-408.
25. Carter BL, Basile J: Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens 2005, 7:638-640.
26. Stevo J, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial. Lancet 2004, 28:221-226.
27. Wright JT, Harris-Haywood S, Pressel S, et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008, 168:207-217.
28. Tan AS, Kuppuswamy S, Whaley-Connell AT, et al.: Recommendations for special populations: the treatment of hypertension in diabetes mellitus. Endocrinologist 2004, 14:368-381.
29. Bank AJ, Kelly AS, Thelen AM, et al.: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hyperten 2007, 20:777-783.
30. Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
31. Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertension 2006, 24:591-596.
32. Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
33. Luft FC, Weinberger MH: Antihypertensive therapy with aliskiren. Kidney Int 2008, 73:679-683.
34. Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261-2266.
35. Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
36. Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
37. Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004-1010.
38. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003, 21:1563-1574.
39. Ichikawa Y: Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331-136.
40. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
41. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
42. Stas S, Whaley-Connell A, Habibi J, et al.: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148:3773-3780.
43. Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.